Page 1,846«..1020..1,8451,8461,8471,848..1,8601,870..»

Category Archives: Transhuman News

Adam and the Genome Part Eighteen – Patheos (blog)

Posted: May 4, 2017 at 2:50 pm

I like the line on p. 140 from Durhams own Venerable Bede Adam had the burden of embarrassment, but not the humility of confession. Scots next comment is near the mark on the same page Every conceivable relationship is affected by their choice, and this infection begins to spread until in 8.21 God can say this of human every inclination of the human heart is evil from childhood.

I agree with the view that the banishment from the garden is to prevent Adam and Eve from eating from the tree of life and becoming everlasting fallen creatures on earth. In other words, I think Adam and Eve were created mortal, just as Jesus himself. Physical Mortality is a natural trait of all creatures before the Fall. Were death simply a product of sin, including the original sins, it would be rather difficult to explain how death on a cross didnt entail Jesus being a sinner. No, the natural limitations of all humans are limitations of time, space, knowledge, power and mortality, none of which are inherently a result of sin. Jesus was like us in all respects, including mortality, save without sin. He had no fallen human nature, and yet he was mortal.

More:
Adam and the Genome Part Eighteen - Patheos (blog)

Posted in Genome | Comments Off on Adam and the Genome Part Eighteen – Patheos (blog)

Team maps genome organization to link retinal development and retinoblastoma – Medical Xpress

Posted: at 2:50 pm

May 4, 2017 Corresponding author Michael Dyer, Ph.D., a Howard Hughes Medical Institute Investigator and St. Jude Department of Developmental Neurobiology chair. Credit: St. Jude Children's Research Hospital

A team from the St. Jude Children's Research Hospital Washington University Pediatric Cancer Genome Project (PCGP) has mapped the intricate changes in the "epigenetic" organization of the nucleus to determine how retinal cells transition from immature cells to mature retinal neurons. The researchers have also mapped the epigenome of retinoblastoma cells as they turn cancerous.

The data are an invaluable resource for discovering the still-unknown cellular origin of retinoblastomathe most common eye cancer in children. Scientists can also explore the data for pathways that trigger adult retinal diseases like age-related macular degeneration and retinitis pigmentosa.

The researchers were led by Michael Dyer, Ph.D., a Howard Hughes Medical Institute Investigator and St. Jude Department of Developmental Neurobiology chair. The work appears in the May 3 issue of the journal Neuron.

Epigenetic controls are molecular switches that turn genes on or off to orchestrate a cell's development from a generic cell to a specialized cell like a neuron. While the "genome" of thousands of individual genes is like data stored on a computer disk, the "epigenome" is like a computer program that controls how stored data are read.

Researchers know that epigenetic malfunctions can drive cancers and degenerative diseases, but they have not cracked the "epigenetic code"the specific changes in the organization of the nucleus that guide each type of cell to differentiate from a progenitor cell to a specialized cell.

The researchers used tools of epigenomic analysis to trace the specific epigenetic switches controlling each of thousands of genes in both mouse and human retinal cells as the cells progressed through development.

Analyzing the data revealed surprises about the epigenetic processes of retinal neuron development, Dyer said. One such surprise was the relative importance of two types of epigenetic control switches for retinal development. One control is DNA methylation, which is a chemical alteration of a gene that switches it on or off. The other control switch is histone modification. Histones are proteins that serve as a scaffold for coiling up the DNA into the tight space of the nucleus.

"The perception of the research community was that DNA methylation was the major epigenetic controller," Dyer said. "But to our surprise, only a small percentage of the changes in gene expression during development had any correlation with DNA methylation. It's at the histone level that we saw the really profound changes during differentiation."

Another unexpected discovery, Dyer said, was the point during development when the immature cells transition from making new tissue by dividing rapidly, to differentiating into a mature retinal neuron.

"It's like flipping a giant switch," Dyer said. "Early in development, all the cells are immature progenitors that are rapidly growing and dividing. Then, when those cells stop growing and start becoming neurons, there was a dramatic shift in the epigenome.

"We thought cells would actively shut down those progenitor growth genes, because it would not want them to reactivate and lead to a tumor," he said. "But instead, many of those genes just went from a very active state into what we call an 'empty' state. The cell didn't make any particular effort to shut them down. On the flip side, those genes needed for differentiation, which were repressed in the progenitor cells, had their epigenetic repression removed."

Mapping the epigenetic changes in developing retinoblastoma mouse and human cells yielded similar important insights, Dyer said. "We still don't know which type of cell gives rise to retinoblastoma," he said. "The tumor cells have a mixed program of progenitor cells and neurons. It appears as though they are stuck at the stage when the epigenetic switch is normally flipped to transition from progenitors to neurons.

"While this study can't answer the origin question, it did narrow down the developmental window when the normal cell becomes a tumor cell," he said. "I would have guessed that it would be very early, when a progenitor was rapidly dividing. But we found that the decision point was during a period when the cells were transitioning from rapid growth to differentiation. This insight will allow us to focus on that stage to better understand how retinoblastomas originate."

Added Robert Fulton, director of technology development at Washington University's McDonnell Genome Institute, which contributed to the sequencing and analysis of the data: "This research is a great example of the value of comprehensive genomic analyses and the insights that can be gainedfrom thorough, well-designed studies. To really understand theorigins of retinoblastoma, we need to look beyond genes to understand how epigenetic changes drive cancer."

The new epigenomic data will also enable scientists to search for epigenetic abnormalities underlying adult retinal disease, Dyer said.

"There are some patients with retinal disease who don't show gene mutations that we know are responsible for disease," he said. "Instead, those people might have mutations in epigenetic controls called 'enhancers.' We've provided the first map of these enhancers in the retina, so researchers can discover such mutations."

Dyer and his colleagues also mapped the three-dimensional organization of the retinal epigenome to discover how retinal cells package their genes in concentric regions of the cell nucleus. The organization makes some genes more available than others to be turned on and off.

"It's like packing a suitcase for a trip," he said. "You put the clothes you need in a suitcase to take with you; but those you don't need, you leave in the closet. In our studies, we're trying to decipher the functional significance of why the retinal cell packs some genes away and makes others more accessible.

"All our data will serve as a key resource for investigators exploring specific questions about retinal development and disease," Dyer said. To make the data readily available to other researchers, he has uploaded it to ProteinPaint, a St. Jude web portal that gives scientists worldwide access to masses of cancer genomic data.

Explore further: New measurements reveal differences between stem cells for treating retinal degeneration

More information: Issam Aldiri et al. The Dynamic Epigenetic Landscape of the Retina During Development, Reprogramming, and Tumorigenesis, Neuron (2017). DOI: 10.1016/j.neuron.2017.04.022

By growing two types of stem cells in a "3-D culture" and measuring their ability to produce retinal cells, a team lead by St. Jude Children's Research Hospital researchers has found one cell type to be better at producing ...

Scientists have uncovered how tumor cells in aggressive uterine cancer can switch disguises and spread so quickly to other parts of the body. In a study published in Neoplasia, researchers at the Washington University School ...

In a new study, researchers at Uppsala University have found evidence of a new principle for how epigenetic changes can occur. The principle is based on an enzyme, tryptase, that has epigenetic effects that cause cells to ...

A review article by researchers at Boston University School of Medicine (BUSM) suggests that epigenetics may be a useful target to stop the growth, spread and relapse of cancer. The findings are published online in Volume ...

A newborn's brain is abuzz with activity. Day and night, it's processing signals from all over the body, from recognizing the wriggles of the child's own fingers and toes to the sound of mommy's or daddy's voice.

Neuroscientists at Tufts University School of Medicine have discovered a new signaling pathway that directly connects two major receptors in the brain associated with learning and memorythe N-methyl-D-aspartate receptor ...

Working with mouse, fly and human cells and tissue, Johns Hopkins researchers report new evidence that disruptions in the movement of cellular materials in and out of a cell's control centerthe nucleusappear to be a ...

A team from the St. Jude Children's Research Hospital Washington University Pediatric Cancer Genome Project (PCGP) has mapped the intricate changes in the "epigenetic" organization of the nucleus to determine how retinal ...

Long assumed to be a mere "relay," an often-overlooked egg-like structure in the middle of the brain also turns out to play a pivotal role in tuning-up thinking circuity. A trio of studies in mice funded by the National Institutes ...

One day, our brains will not work the way they used to, we won't be as "sharp" as we once were, we won't be able to remember things as easily.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

The rest is here:
Team maps genome organization to link retinal development and retinoblastoma - Medical Xpress

Posted in Genome | Comments Off on Team maps genome organization to link retinal development and retinoblastoma – Medical Xpress

Gut Microbiome Could Help Diagnose Liver Disease – Technology Networks

Posted: at 2:49 pm


Technology Networks
Gut Microbiome Could Help Diagnose Liver Disease
Technology Networks
To detect NAFLD earlier and more easily, researchers in the NAFLD Research Center at University of California San Diego School of Medicine, Human Longevity, Inc. and the J. Craig Venter Institute report that the unique microbial makeup of a patient's ...

View original post here:
Gut Microbiome Could Help Diagnose Liver Disease - Technology Networks

Posted in Human Longevity | Comments Off on Gut Microbiome Could Help Diagnose Liver Disease – Technology Networks

Stool microbes predict advanced liver disease: Proof-of-concept … – Science Daily

Posted: at 2:49 pm


Science Daily
Stool microbes predict advanced liver disease: Proof-of-concept ...
Science Daily
Nonalcoholic fatty liver disease (NAFLD) -- a condition that can lead to liver cirrhosis and cancer -- isn't typically detected until well advanced. Even then ...

and more »

See the article here:
Stool microbes predict advanced liver disease: Proof-of-concept ... - Science Daily

Posted in Human Longevity | Comments Off on Stool microbes predict advanced liver disease: Proof-of-concept … – Science Daily

Labiotech’s first ever ticket giveaway – Win a ticket to WPMC 2017 – Labiotech.eu (blog)

Posted: at 2:49 pm

In case you havent heard of this event yet, the World Precision Medicine Congress (WPMC) is an industry gathering in London, bringing together over 600 decision makers, influencers and innovators from across academia, biotech and the pharmaceutical industry.

Whats so special? The awesome team at Terrapinn (the congress organisers) is offering a full pass for free to one lucky Labiotech reader. The pass also includes access to two other joint conferences. More details on that below.

Hear the industry disruptors: Adam Blatt, Global Head of Genomics at AstraZeneca; Susan Solomon, CEO and Co-Founder of the New York Stem Cell Foundation; and more from GSK, Duke University, Human Longevity Project, Novartis and others.

The programme boasts keynote presentations from influential thought leaders in the industry, there are 6 focused tracks to chose from and if that wasnt enough its co-located with the World Advanced Therapies & Regenerative Medicine Congress and World Cord Blood Congress

For more details check out the brochure here!

More on the ticket giveaway:

The World Precision Medicine Congress is partnering with Labiotech to offer a free ticket to attend the conference taking place on 17-19 May in London!

What youll get:

How to take part in the prize draw?

We wish you the best of luck!

P.S. We are planning on teaming up with a few more events, so we can have more giveaways for our awesome readers (thats you!) stay tuned for more! Whats your favourite event, whom should we partner with? Send us a quick email or let us know in the comments.

Image from Corepics VOF /shutterstock.com

See the article here:
Labiotech's first ever ticket giveaway - Win a ticket to WPMC 2017 - Labiotech.eu (blog)

Posted in Human Longevity | Comments Off on Labiotech’s first ever ticket giveaway – Win a ticket to WPMC 2017 – Labiotech.eu (blog)

Fatty liver: Diagnosis of advanced fibrosis from stool microbes shows promise – Medical News Today

Posted: at 2:49 pm

Nonalcoholic fatty liver disease affects millions of people in the United States. The condition is often not detected until it is well advanced, and a definitive diagnosis requires an invasive biopsy of the liver. One subtype can lead to severe liver cirrhosis and cancer. Now, promising results from a preliminary study set the stage for a noninvasive test that only requires a stool sample. The test examines the makeup of gut microbes in the stool sample.

The study - by researchers from the University of California-San Diego (UCSD) and colleagues from Human Longevity, Inc. in San Diego and the J. Craig Venter Institute in La Jolla, both in California - is published in the journal Cell Metabolism.

Nonalcoholic fatty liver disease (NAFLD) is a condition characterized by a buildup of fat in the liver. According to the National Institute of Diabetes and Digestive and Kidney Diseases, it is "one of the most common causes of liver disease in the U.S."

NAFLD is a different condition to alcoholic liver disease, in which the fat buildup is due to heavy alcohol use.

In the new study - which involved 135 participants and establishes "proof of concept" - the researchers found that the stool-based test was able to predict advanced NAFLD with an accuracy of between 88 and 94 percent.

First author Rohit Loomba, a professor of medicine and director of the NAFLD Research Center at UCSD, says that determining who has or is at risk for NAFLD is a "critical unmet medical need."

Although there are dozens of new drugs in the pipeline, if it were possible to better diagnose the disease, then patients could be better selected for trials and "ultimately [we] will be better equipped to prevent and treat it," Prof. Loomba adds.

There are two forms of NAFLD: simple fatty liver and nonalcoholic steatohepatitis (NASH).

Fast facts about NAFLD

Learn more about NAFLD

Simple fatty liver is a form of NAFLD in which there is fat in the liver but without inflammation or cell damage. This form does not usually lead to liver damage or complications.

NASH is type of NAFLD where, in addition to fat buildup, the liver also shows signs of inflammation and liver cell damage.

The inflammation can lead to scarring or fibrosis, and then to more severe cirrhosis, which alters the liver's fundamental biology. NASH can also progress to liver cancer.

Nobody knows exactly what causes NAFLD, or why some of the people affected have simple fatty liver while others have NASH.

Estimates suggest that around 20 percent of people with NAFLD have NASH. In the U.S., between 30 and 40 percent of adults are thought to have NAFLD, and approximately 3 to 12 percent have NASH.

Being obese - and having conditions related to obesity, such as type 2 diabetes - raises the risk of developing NAFLD.

Prof. Loomba and colleagues note that NAFLD is thought to affect up to 50 percent of obese people.

In their study report, the researchers note how studies have shown that the makeup of a person's gut microbiome - the trillions of microbes that live in the gut together with their genetic material - may affect their risk for obesity.

This set them wondering if there might also be a link between obesity-related liver disease and the gut microbiome. If this is true, then it may be possible to analyze the makeup of the gut microbiome from a person's stool sample and link that to their NAFLD status.

To test this theory, the team first examined 86 patients with NAFLD diagnosed by biopsy - including 72 with mild or moderate disease and 14 with advanced disease.

They sequenced the genes from the participants' stool samples - analyzing the presence, location, and relative abundance of various microbe species.

This process identified 37 species of bacteria that differentiated advanced NAFLD from the mild or moderate stage with 93.6 percent accuracy.

The researchers then validated the finding in a second group of 16 patients with advanced NAFLD and 33 healthy volunteers who acted as controls.

This time, they found that by testing the relative abundance of nine species of bacteria - seven of which were in the 37 identified previously - they could differentiate the NAFLD patients from the controls with 88 percent accuracy.

"We believe our study sets the stage for a potential stool-based test to detect advanced liver fibrosis based simply on microbial patterns, or at least help us minimize the number of patients who have to undergo liver biopsies."

Senior author Dr. Karen E. Nelson, president of the J. Craig Venter Institute

The researchers are keen to point out that so far, the test has only been trialed on a small number of patients in a highly specialized setting. Even if further studies validate it, a stool sample test for NAFLD is unlikely to be available for clinical use for at least 5 years.

Learn how a protein discovery may offer a new treatment target for NAFLD.

The rest is here:
Fatty liver: Diagnosis of advanced fibrosis from stool microbes shows promise - Medical News Today

Posted in Human Longevity | Comments Off on Fatty liver: Diagnosis of advanced fibrosis from stool microbes shows promise – Medical News Today

Atopic Eczema – Patient

Posted: at 2:49 pm

Atopic eczema is an inflammation of the skin, which tends to flare up from time to time. It usually starts in early childhood. The severity can range from mild to severe. There is no cure but treatment can usually control or ease symptoms. Moisturisers (emollients) and steroid creams or ointments are the common treatments. About 2 in 3 children with atopic eczema grow out of it by their mid-teens.

Eczema is sometimes called dermatitis which means inflammation of the skin. There are different types of eczema. The most common type is atopic eczema. In this type of eczema there is a typical pattern of skin inflammation which causes the symptoms.

The word atopic describes people with certain allergic tendencies. However, atopic eczema is not just a simple allergic condition. People with atopic eczema have an increased chance of developing other atopic conditions, such as asthma and hay fever.

Typically, inflamed areas of skin tend to flare up from time to time and then tend to settle down. The severity and duration of flare-ups varies from person to person and from time to time in the same person.

Most cases first develop in children under the age of five years. It is unusual to develop atopic eczema for the first time after the age of 20. At the moment, about 1 in 5 schoolchildren have some degree of atopic eczema. However, statistics show that it is becoming more common year on year. In about 2 in 3 cases, by the mid-teenage years, the flare-ups of eczema have either gone completely, or are much less of a problem. However, there is no way of predicting which children will still be affected as adults.

Between 1-5 in 20 adults have atopic eczema.

The cause is not known. The oily (lipid) barrier of the skin tends to be reduced in people with atopic eczema. This leads to an increase in water loss and a tendency towards dry skin. Also, some cells of the immune system release chemicals under the skin surface, which can cause some inflammation. But it is not known why these things occur. Inherited (genetic) factors play a part. Atopic eczema occurs in about 8 in 10 children where both parents have the condition and in about 6 in 10 children where one parent has the condition. The precise genetic cause is not clear (which genes are responsible, what effects they have on the skin, etc). However, recent research suggests that in some people genetic changes hamper the production of a chemical (filaggrin) involved in the defence barrier of the skin.

As mentioned previously, atopic eczema is becoming more common. There is no proven single cause for this but factors which may play a part include:

There may be a combination of factors in someone who is genetically prone to eczema, which causes the drying effect of the skin and the immune system to react and cause inflammation in the skin.

The usual treatment consists of three parts:

Many people with atopic eczema have flare-ups from time to time for no apparent reason. However, some flare-ups may be caused (triggered) or made worse by irritants to the skin, or by other factors. It is commonly advised to:

House dust mite is a tiny insect that occurs in every home. You cannot see it without a microscope. It mainly lives in bedrooms and mattresses as part of the dust. Many people with atopic eczema are allergic to house dust mite. If you are allergic, you have to greatly reduce the numbers of house dust mite for any chance that symptoms may improve.

However, it is impossible to clear house dust mite completely from a home and it is hard work to reduce their number to a level which may be of benefit. It involves regular cleaning and vacuuming with particular attention to your bedroom, mattress and bedclothes.

Therefore, in general, it is not usually advised to do anything about house dust mite - especially if your eczema is mild-to-moderate and can be managed by the usual treatments of emollients and short courses of topical steroids. However, if you have moderate or severe atopic eczema which is difficult to control with the usual treatments, you may wish to consider reducing the number of house dust mites in your home. See separate leaflet called House Dust Mite and Pet Allergy, which gives more details on how to reduce house dust mites.

About 1 in 2 children with atopic eczema have a food allergy which can make symptoms worse. In general, it is young children with severe eczema who may have a food sensitivity as a trigger factor. The most common foods which trigger symptoms in some people include cow's milk, eggs, soya, wheat, fish and nuts.

If you suspect a food is making your child's symptoms worse then see a doctor. You may be asked to keep a diary over 4-6 weeks. The diary aims to record any symptoms and all foods and drink taken. It may help to identify one or more suspect foods. If food allergy is suspected, it should be confirmed by a specialist. They may recommend a diet without this food if the eczema is severe and difficult to control by other means.

Other possible factors which may trigger symptoms, or make symptoms worse, include:

However, some of these may not be avoidable.

See separate leaflet in this series, called Eczema - Triggers and Irritants, for more details.

People with atopic eczema have a tendency for their skin to become dry. Dry skin tends to flare up and become inflamed into patches of eczema. Emollients are lotions, creams, ointments and bath/shower additives which prevent the skin from becoming dry. They oil the skin, keep it supple and moist and help to protect the skin from irritants. This helps to prevent itch and helps to prevent or to reduce the number of eczema flare-ups.

The regular use of emollients is the most important part of the day-to-day treatment for atopic eczema. Your doctor, nurse or pharmacist can advise on the various types and brands available and the ones which may suit you best.

You should apply emollients as often as needed. This may be twice a day, or several times a day if your skin becomes very dry. Some points about emollients include:

Many people with atopic eczema use a range of different emollients. For example, a typical routine for a person with moderately severe atopic eczema might be:

Note: emollients used for eczema tend to be bland and non-perfumed. Occasionally, some people become allergic (sensitised) to an ingredient in an emollient. This can make the skin worse rather than better. If you suspect this, see your doctor for advice. There are many different types of emollients with various ingredients. A switch to a different type will usually sort out this uncommon problem.

Warning: bath additive emollients will coat the bath and make it greasy and slippery. It is best to use a mat and/or grab rails to reduce the risk of slipping. Warn anybody else who may use the bath that it will be slippery.

See separate leaflet called Moisturisers (Emollients) for Eczema for more details.

Topical steroids work by reducing inflammation in the skin. (Steroid medicines that reduce inflammation are sometimes called corticosteroids. They are very different to the anabolic steroids which are used by some bodybuilders and athletes.) Topical steroids are grouped into four categories depending on their strength - mild, moderately potent, potent and very potent. There are various brands and types in each category. For example, hydrocortisone cream 1% is a commonly used steroid cream and is classed as a mild topical steroid. The greater the strength (potency), the more effect it has on reducing inflammation but the greater the risk of side-effects with continued use.

Creams are usually best to treat moist or weeping areas of skin. Ointments are usually best to treat areas of skin which are dry or thickened. Lotions may be useful to treat hairy areas such as the scalp.

As a rule, a course of topical steroid is used when one or more patches of eczema flare up. You should use topical steroids until the flare-up has completely gone and then stop them. In many cases, a course of treatment for 7-14 days is enough to clear a flare-up of eczema. In some cases, a longer course is needed. Many people with atopic eczema require a course of topical steroids every now and then to clear a flare-up. The frequency of flare-ups and the number of times a course of topical steroids is needed can vary greatly from person to person.

It is common practice to use the lowest-strength topical steroid which clears the flare-up. If there is no improvement after 3-7 days, a stronger topical steroid is usually then prescribed. For severe flare-ups a stronger topical steroid may be prescribed from the outset. Sometimes two or more preparations of different strengths are used at the same time. For example, a mild steroid for the face and a stronger steroid for patches of eczema on the thicker skin of the arms or legs.

For adults, a short course (usually three days) of a strong topical steroid may be an option to treat a mild-to-moderate flare-up of eczema. A strong topical steroid often works quicker than a mild one. (This is in contrast to the traditional method of using the lowest strength wherever possible. However, studies have shown that using a high strength for a short period can be more convenient and is thought to be safe.)

Some people have frequent flare-ups of eczema. For example, a flare-up may subside well with topical steroid therapy. But then, within a few weeks, a flare-up returns. In this situation, one option that might help is to apply steroid cream on the usual sites of flare-ups for two days every week. This is often called weekend therapy. This aims to prevent a flare-up from occurring. In the long run, it can mean that the total amount of topical steroid used is less than if each flare-up were treated as and when it occurred. You may wish to discuss this option with your doctor.

Topical steroids are usually applied once a day but this may be increased to twice a day if there is no improvement. Rub a small amount thinly and evenly just on to areas of skin which are inflamed. (This is different to moisturisers (emollients) which should be applied liberally all over.)

To work out how much you should use each dose: squeeze out some cream or ointment from the tube on to the end of an adult finger - from the tip of the finger to the first crease. This is called a fingertip unit. One fingertip unit is enough to treat an area of skin twice the size of the flat of an adult's hand with the fingers together. Gently rub the cream or ointment into the skin until it has disappeared. Then wash your hands (unless your hands are the treated area).

Note: don't forget you can use emollients as well when you are using a course of topical steroids.

See separate leaflet called Fingertip Units for Topical Steroids for more details.

Short courses of topical steroids (fewer than four weeks) are usually safe and normally cause no problems. Problems may develop if topical steroids are used for long periods, or if short courses of strong topical steroids are repeated often. The concern is mainly if strong topical steroids are used in the long term. Side-effects from mild topical steroids are uncommon.

For more details about side-effects see separate leaflet called Topical Steroids for Eczema for more details.

Most people with eczema will be prescribed emollients to use every day and a topical steroid to use when flare-ups develop. When using the two treatments, apply the emollient first. Wait 10-15 minutes after applying an emollient before applying a topical steroid. That is, the emollient should be allowed to sink in (be absorbed) before a topical steroid is applied. The skin should be moist or slightly tacky but not slippery, when applying the steroid.

Sometimes, one or more patches of eczema become infected during a flare-up. Characteristics of infected eczema include:

If the infection becomes more severe, you may also develop a high temperature (fever) and generally feel unwell. If infected eczema develops then a course of an antibiotic tablet or liquid medicine will usually clear the infection. This is used in addition to usual eczema topical treatments. Sometimes, a topical antibiotic is used if the infection is confined to a small area.

Once the infection is cleared, it is best to throw away all your usual creams, ointments and lotions and obtain fresh new supplies. This is to reduce the risk of applying creams, etc that may have become contaminated with germs (bacteria). Also, if you seem to have repeated bouts of infected eczema, you may be advised to use a topical antiseptic such as chlorhexidine on a regular basis. This is in addition to your usual treatments. The aim is to keep the number of bacteria on your skin to a minimum.

See your doctor if a flare-up of atopic eczema is getting worse or not clearing despite the usual treatments with moisturisers (emollients) and topical steroids. Things which may be considered include:

You may be referred to a skin specialist if a flare-up does not improve with the usual treatments.

Alternative remedies such as herbal medicines are sometimes tried by some people. However, you should be cautious about using them, especially if their labels are not in English and you are not sure what they contain. Some herbal treatments are mixed with steroids and some (particularly Chinese remedies) have been linked to liver damage.

It may be worth breast-feeding a newborn baby for three months or more if several members of the family suffer from allergies such as eczema, hay fever or asthma. There is, however, no evidence to suggest that the mother should avoid any particular foods during pregnancy or breast-feeding.

Perioral dermatitis - my wedding in 2 months!!

Red Skin Syndrome re: worsening atopic dermatitis

Clobetasol Propionate Ointment 0.5%

Continued here:
Atopic Eczema - Patient

Posted in Eczema | Comments Off on Atopic Eczema – Patient

Topical Steroid Use in Psoriasis Patient Leads to Severe Adrenal Insufficiency – Monthly Prescribing Reference (registration)

Posted: at 2:48 pm

May 04, 2017

For 18 years, the patient applied Clobetasol Propionate 0.05% daily on several areas of his body

This article is written live from the American Association of Clinical Endocrinologists (AACE) 2017 Annual Meeting in Austin, TX. MPR will be reporting news on the latest findings from leading experts in endocrinology. Check back for more news from AACE 2017.

At the AACE 2017 Annual Meeting, lead study author Kaitlyn Steffensmeier, MS III, of the Dayton Veterans Affairs (VA) Medical Center, Dayton, OH, presented a case study describing a patient who developed secondary adrenal insufficiency secondary to long-term topical steroid use and who with decreased topical steroid use recovered.

The patient was a 63-year-old white male with a 23-year history of psoriasis. For 18 years, the patient had been applying Clobetasol Propionate 0.05% topically on several areas of his body every day. Upon presentation to the endocrine clinic for evaluation of his low serum cortisol, the patient complained of a 24-pound weight gain over a 2-year period, feeling fatigued, as well as facial puffiness.

Laboratory analysis found that the patient's random serum cortisol and ACTH levels were low (0.2g/dL and <1.1pg/mL, respectively). According to the study authors, the labs were indicative of secondary adrenal insufficiency. Additionally, a pituitary MRI showed a 2mm hypoenhancing lesion within the midline of the pituitary gland consistent with Rathke's cleft cyst versus pituitary microadenoma.

The patient was initiated on 10mg of hydrocortisone in the morning and 5mg in the evening and was instructed to decrease the use of his topical steroid to one time per month. For the treatment of his psoriasis, the patient was started on apremilast, a phosphodiesterase-4 enzyme (PDE4) inhibitor, and phototherapy.

After 2.5 years, the patient had a subnormal response to the cosyntropin stimulation test. However, after 3 years, a normal response with an increase in serum cortisol to 18.7g/dL at 60 minutes was obtained; the patient was then discontinued on hydrocortisone. Additionally, a stable pituitary tumor was shown via a repeat pituitary MRI.

The study authors explained that, although secondary adrenal insufficiency is not commonly reported, one study showed 40% of patients with abnormal cortisol response to exogenous ACTH after two weeks of topical glucocorticoids usage. Another meta-analysis of 15 studies (n=320) revealed 4.7% of patients developing adrenal insufficiency after using topical steroids. Because of this, clinicians need to be aware of potential side effects of prolong topical steroid use, added the study authors.

For continuous endocrine news coverage from the AACE 2017 Annual Meeting, check back to MPR's AACE page for the latest updates.

Go here to read the rest:
Topical Steroid Use in Psoriasis Patient Leads to Severe Adrenal Insufficiency - Monthly Prescribing Reference (registration)

Posted in Psoriasis | Comments Off on Topical Steroid Use in Psoriasis Patient Leads to Severe Adrenal Insufficiency – Monthly Prescribing Reference (registration)

UK GPs lacking in psoriasis training, warns report – PharmaTimes

Posted: at 2:48 pm

A new report by The Patient Association in association with LEO Pharma has highlighted the significant gap between training/support available in primary care and the needs of people living with psoriasis in the UK and Ireland.

Nearly two million people are currently living with psoriasis - a common, serious, lifelong, incurable autoimmune disease - in Great Britain and Ireland. Around 80 percent of patients have chronic plaque psoriasis, which is characterised by thickened, scaly plaques on the surface of the skin causing scaling, itching, stinging, burning and bleeding.

According to the PSO What? report, psoriasis costs the UK economy over 1.07 billion in lost productivity alone, and also represents a significant drag on health services, accounting for 5 percent of GP dermatology consultations in England and Wales. And yet this workload is not balanced by adequate dermatology education for GPs and there is a chronic shortage of dermatologists, the report notes. GPs have little dermatology training and education and there are only 650 consultants to advise them, and provide more specialist care.

Currently there is no compulsory requirement for dermatology training within undergraduate or postgraduate curricula. In some cases, training is less than five days, despite a minimum of two weeks recommended within the 2006 dermatology curricula, distributed to all medical schools.

It is a serious concern that there appears to be an inverse training law in operation in dermatology, whereby in the area which is most routinely seen by GPs, the amount of training is the least, says the The British Association of Dermatologists.

It is important that medical professionals who are treating psoriasis are adequately trained and offer a full service (including the exploration of how each patients condition is affecting both their mental and physical health, and the regular review of the effectiveness of treatments) if they are to contribute towards their patients successful management of their conditions.

A survey conducted as part of the PSO What? initiative also reveals that GPs admit to lacking in knowledge and understanding regarding the effective management of the condition which, it warns, is particularly concerning given people with psoriasis are also at risk of developing other serious associated conditions, such as psoriatic arthritis, cardiovascular disease, inflammatory bowel disease, liver disease, complications with vision and some cancers.

This new report shines a light on the shortcomings of dermatological training and staffing, which inevitably give rise to sub-optimal psoriasis care. It is essential these issues are addressed if we are to improve patient outcomes, and reduce the burden of the associated comorbidities currently weighing on individuals, health services, the economy, and society as a whole, said Katherine Murphy, chief executive of the Patients Association.

Dr Anthony Bewley, consultant dermatologist at Whipps Cross and St Barts NHS Trust, said it is essential that the current lack of training and formal assessment of practical dermatology skills is addressed.

Beyond that, we, as healthcare professionals, need to move away from the misconception that psoriasis is just a skin condition, and look for the best possible whole-person care for each individual. The unfortunate truth is that past failings have seen some patients simply slip through the net. The PSO What? report signals a sea-change, encouraging patients to demand more from their doctors, and to make sure that medical professionals do not undermine their experience of living with psoriasis.

Go here to see the original:
UK GPs lacking in psoriasis training, warns report - PharmaTimes

Posted in Psoriasis | Comments Off on UK GPs lacking in psoriasis training, warns report – PharmaTimes

Cannabinoids May Soothe Eczema, Psoriasis, Other Skin Diseases, Study Finds – Study Finds

Posted: at 2:48 pm

AURORA, Colo. Individuals with skin diseases may be able to find relief with the use of non-psychotropic topical cannabinoids. A new study finds that the cannabis-based creamsmay be helpful in treating a wide range of skin illness, including psoriasis, eczema, atopic and contact dermatitis, inflammatory skin disease, and skin cancer.

Researchers at the University of Colorado Anschutz Medical Campus reviewed the current literature on treating skin disease with topical cannabinoids and concluded that cannabinoids anti-inflammatory properties may help to reduce patients dry skin and itching.

In one of the studies included, eight out of 21 patients using a cannabinoid cream on their skin twice daily for three weeks experienced the complete elimination of pruritus (severe itching).

Perhaps the most promising role for cannabinoids is in the treatment of itch, the studys senior author Dr. Robert Dellavalle, M.D., associate professor of dermatology at the University of Colorado School of Medicine, says in a press release. These are topical cannabinoid drugs with little or no psychotropic effect that can be used for skin disease.

LIKE STUDIES? FOLLOW STUDYFINDS.ORG ON FACEBOOK!

The study abstract explains that 28 U.S. states run comprehensive medical cannabis programs and that almost one in 10 adult users have medical reasons for cannabis use. Cannabis is also currently being studied for the treatment of nausea, spasticity, chronic pain, anorexia and other ailments. Dellavalle stated that THC, or tetrahydrocannabinol, which is the active ingredient in marijuana, has reduced swelling, inflammation and even tumor growth in mice. Large-scale clinical trials have not yet occurred.

These diseases cause a lot of problems for people and have a direct impact on their quality of life, Dellavalle says of treating skin ailments with cannabinoids. The treatments are currently being bought over the internet and we need to educate dermatologists and patients about the potential uses of them.

These findings were published in The role of cannabinoids in dermatology in the Journal of the American Academy of Dermatology.

Go here to read the rest:
Cannabinoids May Soothe Eczema, Psoriasis, Other Skin Diseases, Study Finds - Study Finds

Posted in Psoriasis | Comments Off on Cannabinoids May Soothe Eczema, Psoriasis, Other Skin Diseases, Study Finds – Study Finds

Page 1,846«..1020..1,8451,8461,8471,848..1,8601,870..»